Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 3/2014

01-05-2014

Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases

Authors: Adam Mohmand-Borkowski, W. H. Wilson Tang

Published in: Heart Failure Reviews | Issue 3/2014

Login to get access

Abstract

While atrial fibrillation is common comorbidity in patients with cardiomyopathy and heart failure, diagnosis and management often focuses on tackling rate and rhythm control rather than elucidating pathogenic mechanisms related to underlying myocardial substrates. This review summarizes our current understanding of the natural history of cardiomyopathies presenting with atrial fibrillation, and the importance of managing underlying cardiomyopathic condition as diagnostic and treatment strategy for atrial fibrillation.
Literature
1.
Wang TJ et al (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham heart study. Circulation 107:2920–2925PubMedCrossRef
2.
3.
Kannel WB et al (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A):2N–9NPubMedCrossRef
4.
Tedesco MA et al (2001) Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 24:603–607PubMedCrossRef
5.
Hammwohner M, Goette A (2011) Evidence for mechano-electric coupling from clinical trials on AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 395–401
6.
Kalifa J et al (2003) Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108:668–671PubMedCrossRef
7.
Franz MR, Bode F (2011) Acute stretch effects on atrial electrophysiology. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 168–172
8.
Camm J et al (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429PubMedCrossRef
9.
Kamkin A et al (2000) Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48(3):409–420PubMedCrossRef
10.
Spach MS et al (2001) Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol 34(Suppl):69–76PubMedCrossRef
11.
Schotten U (2011) Mechano-electric coupling from in chronic AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 204–211
12.
13.
14.
Kottkamp H (2012) Atrial fibrillation substrate: the “unknown species”—from lone atrial fibrillation to fibrotic atrial cardiomyopathy. Heart Rhythm 9(4):481–482PubMedCrossRef
15.
Mahnkopf C et al (2010) Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 7:1475–1481PubMedCentralPubMedCrossRef
16.
Oakes RS et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119:1758–1767PubMedCentralPubMedCrossRef
17.
Teh AW et al (2012) Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 9(4):473–480PubMedCrossRef
18.
19.
Darby AE, Dimarco JP (2012) Management of atrial fibrillation in patients with structural heart disease. Circulation 125(7):945–957PubMedCrossRef
20.
Bunch TJ et al (2008) Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 19:1009–1014PubMedCrossRef
21.
Kilicaslan F et al (2006) Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 3(3):275–280PubMedCrossRef
22.
Di Donna P et al (2010) Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 12:347–355PubMedCrossRef
23.
Seidman JE, Pyeritz RE, Seidman CE (2012) Inherited causes of cardiovascular disease. In: Bonow R, Mann D, Zipes D, Libby P (eds) Braunwald’s heart disease a textbook of cardiovascular medicine, 9th edn. Elsevier, Amsterdam, pp 70–79CrossRef
24.
Maron BJ et al (2009) Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301(12):1253–1259PubMedCrossRef
25.
Bounce D et al (2011) Natural history of Danon disease. Genet Med 13(6):563–568CrossRef
26.
Cheng Z, Cui Q, Tian Z et al (2012) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 33(5):649–656PubMedCrossRef
27.
Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17:229–234PubMedCrossRef
28.
29.
30.
Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH (2013) Isolated left ventricular noncompaction controversies in diagnosis. Heart 99(10):681–689PubMedCrossRef
31.
Connolly HM, Attenhofer JC (2013) Isolated left ventricular non-compaction. UpToDate
32.
Ammash NA, Tajik JA (2013) Idiopathic restrictive cardiomyopathy. UpToDate
33.
Falk R, Dubrey S (2010) Amyloid heart disease. In: Gertz MA, Rajkumar SV (eds) Amyloidosis: diagnosis and treatment. Humana Press, Clifton, pp 107–128CrossRef
34.
Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420PubMedCrossRef
35.
Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497
36.
Redfield MM et al (2000) Tachycardia related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for AV node ablation. Mayo Clin Proc 75:790–795PubMedCrossRef
37.
Deshmukh PM et al (2004) Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 13:455–464PubMed
38.
Moe GW et al (1993) Left ventricular myocardial blood flow, metabolism and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 131:294–302
39.
Spinale FG et al (1992) Myocardial Na, K-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 24:277–289PubMedCrossRef
40.
Kloner RA et al (1981) Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci USA 78:7152–7163PubMedCentralPubMedCrossRef
41.
Huffman C et al (2010) Reversible cardiomyopathies—a review. Transpl Proc 42(9):3673–3678CrossRef
42.
Iyer VR (2008) Ventricular dysfunction: tachycardia induced cardiomyopathy. Indian Pacing Electrophysiol J 8(Suppl 1):S122–S129
43.
Watanabe H et al (2008) Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 49(1):39–47PubMedCrossRef
44.
Jeong Y et al (2008) Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31(4):172–178PubMedCrossRef
45.
Gentlesk PJ et al (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18(1):9–14PubMedCrossRef
46.
Nerheim P et al (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110(3):247–252PubMedCrossRef
47.
Ling L et al (2013) Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy following successful ablation. Circ Arrhythm Electrophysiol 6(4):697–704PubMedCrossRef
48.
Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRef
49.
Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention. EuroPace 13:610–662PubMedCrossRef
50.
Camm J et al (2012) Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747PubMedCrossRef
Metadata
Title
Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases
Authors
Adam Mohmand-Borkowski
W. H. Wilson Tang
Publication date
01-05-2014
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 3/2014
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-014-9424-0

Other articles of this Issue 3/2014

Heart Failure Reviews 3/2014 Go to the issue

OriginalPaper

Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation

OriginalPaper

Atrial fibrillation in heart failure: catheter and surgical interventional therapies

OriginalPaper

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control

OriginalPaper

New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment

OriginalPaper

Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures

OriginalPaper

Clinical use of novel biomarkers in heart failure: towards personalized medicine

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits